{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:29:01Z","timestamp":1771928941429,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Kidney involvement represents one of the main targets of the systemic inflammatory process and is underscored by a heterogeneous pathology ranging from amyloidosis to non-amyloid-related damage rooted in inflammasome activation. A thorough approach to monogenic autoinflammatory disorders (AIDs) includes identifying phenotypic patterns, comprehending pathophysiology, and customizing therapy to improve patients' quality of life. In this review, we will discuss some pharmacological aspects focusing on the kidney as a target in AIDs. A special emphasis will be placed on medications used for AIDs cases with renal impairment, as well as drug-induced nephrotoxicity in monogenic AIDs. Understanding the mechanisms of drug-induced nephrotoxicity and applying preventive measures are critical for safely managing monogenic AIDs with renal involvement.<\/jats:p>","DOI":"10.1186\/s40001-026-03936-6","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:56:59Z","timestamp":1770901019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacologic management of renal involvement in monogenic autoinflammatory diseases"],"prefix":"10.1186","volume":"31","author":[{"given":"Ahmed","family":"Fayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Tharwat","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Gaggiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaafar","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"3936_CR1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9279-21","author":"K Migita","year":"2022","unstructured":"Migita K, Fujita Y, Asano T, Sato S. The expanding spectrum of autoinflammatory diseases. Intern Med. 2022. https:\/\/doi.org\/10.2169\/internalmedicine.9279-21.","journal-title":"Intern Med"},{"key":"3936_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1147202","volume":"14","author":"T Mukai","year":"2023","unstructured":"Mukai T, Ida H, Ueki Y, Nishikomori R. Editorial: a new frontier in translational research on autoinflammatory diseases\u2014various aspects of innate immunity on human diseases. Front Immunol. 2023;14:1147202.","journal-title":"Front Immunol"},{"key":"3936_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.565099","volume":"11","author":"W Wang","year":"2020","unstructured":"Wang W, Yu Z, Gou L, Zhong L, Li J, Ma M, et al. Single-center overview of pediatric monogenic autoinflammatory diseases in the past decade: a summary and beyond. Front Immunol. 2020;11:565099.","journal-title":"Front Immunol"},{"issue":"7","key":"3936_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/nep.14166","volume":"28","author":"S La Bella","year":"2023","unstructured":"La Bella S, Di Ludovico A, Di Donato G, Scorrano G, Chiarelli F, Vivarelli M, et al. Renal involvement in monogenic autoinflammatory diseases: A narrative review. Nephrology (Carlton, Vic). 2023;28(7):363\u201371.","journal-title":"Nephrology (Carlton, Vic.)"},{"issue":"suppl 110","key":"3936_CR5","first-page":"54","volume":"36","author":"R Scarpioni","year":"2018","unstructured":"Scarpioni R, Obici L. Renal involvement in autoinflammatory diseases and inflammasome-mediated chronic kidney damage. Clin Exp Rheumatol. 2018;36(suppl 110):54\u201360.","journal-title":"Clin Exp Rheumatol."},{"key":"3936_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41419-023-06005-6","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Lei H, Zhang W, et al. Pyroptosis in renal inflammation and fibrosis: current knowledge and clinical significance. Cell Death Dis. 2023;14:472.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3936_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000529917","volume":"9","author":"C Zhang","year":"2023","unstructured":"Zhang C, Peng J, Liu Z, Zhou Q. Kidney involvement in autoinflammatory diseases. Kidney Dis (Basel). 2023;9(3):157\u201372.","journal-title":"Kidney Dis (Basel)"},{"issue":"3","key":"3936_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000529917","volume":"9","author":"C Zhang","year":"2023","unstructured":"Zhang C, Peng J, Liu Z, Zhou Q. Kidney involvement in autoinflammatory diseases. Kidney Dis. 2023;9(3):157\u201372.","journal-title":"Kidney Dis"},{"key":"3936_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.935957","volume":"13","author":"S Signa","year":"2022","unstructured":"Signa S, Bertoni A, Penco F, Caorsi R, Cafaro A, Cangemi G, et al. Adenosine deaminase 2 deficiency (DADA2): a crosstalk between innate and adaptive immunity. Front Immunol. 2022;13:935957.","journal-title":"Front Immunol"},{"issue":"3","key":"3936_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2022.12.816","volume":"151","author":"Y Du","year":"2023","unstructured":"Du Y, Liu M, Nigrovic PA, Dedeoglu F, Lee PY. Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children. J Allergy Clin Immunol. 2023;151(3):607\u201318.","journal-title":"J Allergy Clin Immunol"},{"key":"3936_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00865","volume":"11","author":"A Soriano","year":"2020","unstructured":"Soriano A, Soriano M, Espinosa G, Manna R, Emmi G, Cantarini L, et al. Current therapeutic options for the main monogenic autoinflammatory diseases and PFAPA syndrome: evidence-based approach and proposal of a practical guide. Front Immunol. 2020;11:865.","journal-title":"Front Immunol"},{"key":"3936_CR12","unstructured":"Arnold DD, Yalamanoglu A, Boyman O. Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders. Front Immunol."},{"issue":"7","key":"3936_CR13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/annrheumdis-2021-221801","volume":"81","author":"M Romano","year":"2022","unstructured":"Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron KS, et al. The 2021 EULAR\/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann Rheum Dis. 2022;81(7):907\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3936_CR14","first-page":"748","volume":"83","author":"S Bindoli","year":"2024","unstructured":"Bindoli S, De Matteis A, Mitrovic S, Fautrel B, Carmona L, De Benedetti F. Efficacy and safety of therapies for Still\u2019s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR\/PReS guidelines for the management of Still\u2019s disease. Ann Rheum Dis. 2024;83(5):748\u201359.","journal-title":"Ann Rheum Dis"},{"key":"3936_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.516427","volume":"12","author":"T Welzel","year":"2021","unstructured":"Welzel T, Benseler SM, Kuemmerle-Deschner JB. Management of monogenic IL-1 mediated autoinflammatory diseases in childhood. Front Immunol. 2021;12:516427.","journal-title":"Front Immunol"},{"key":"3936_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152089","volume":"57","author":"J Sota","year":"2022","unstructured":"Sota J, Vitale A, Lopalco G, et al. Efficacy and safety of tocilizumab in adult-onset Still\u2019s disease: real-life experience from the international AIDA registry. Semin Arthritis Rheum. 2022;57:152089. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152089.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"3936_CR17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jaci.2021.07.028","volume":"148","author":"YJ Crow","year":"2021","unstructured":"Crow YJ, Neven B, Fr\u00e9mond ML. JAK inhibition in the type I interferonopathies. J Allergy Clin Immunol. 2021;148(4):991\u20133.","journal-title":"J Allergy Clin Immunol"},{"key":"3936_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fsurg.2019.00036","volume":"6","author":"PR Kothapalli","year":"2019","unstructured":"Kothapalli PR, Wyler von Ballmoos MC, Chinnadurai P, Lumsden AB, Ramchandani MK. Value of the hybrid operating theater for an integrated approach to diagnosis and treatment of pulmonary nodules in 2019. Front Surg. 2019;6:36.","journal-title":"Front Surg"},{"issue":"5","key":"3936_CR19","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s10067-021-06006-w","volume":"41","author":"AE Beshlawy","year":"2022","unstructured":"Beshlawy AE, Zekri AER, Ramadan MS, Selim YMM, Abdel-Salam A, Hegazy MT, et al. Genotype-phenotype associations in familial Mediterranean fever: a study of 500 Egyptian pediatric patients. Clin Rheumatol. 2022;41(5):1511\u201321. https:\/\/doi.org\/10.1007\/s10067-021-06006-w.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"3936_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123824","volume":"12","author":"OK Burn","year":"2020","unstructured":"Burn OK, Prasit KK, Hermans IF. Modulating the tumour microenvironment by intratumoural injection of pattern recognition receptor agonists. Cancers (Basel). 2020;12(12):3824. https:\/\/doi.org\/10.3390\/cancers12123824.","journal-title":"Cancers (Basel)"},{"key":"3936_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.930305","volume":"10","author":"F Della Casa","year":"2022","unstructured":"Della Casa F, Vitale A, Cattalini M, et al. Development and implementation of the AIDA International Registry for patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis syndrome. Front Pediatr. 2022;10:930305.","journal-title":"Front Pediatr"},{"issue":"7","key":"3936_CR22","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s11739-022-03038-1","volume":"17","author":"A Vitale","year":"2022","unstructured":"Vitale A, Della Casa F, Ragab G, et al. Development and implementation of the AIDA International Registry for patients with Beh\u00e7et\u2019s disease. Intern Emerg Med. 2022;17(7):1977\u201386.","journal-title":"Intern Emerg Med"},{"key":"3936_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.908501","volume":"9","author":"F Della Casa","year":"2022","unstructured":"Della Casa F, Vitale A, Lopalco G, et al. Development and implementation of the AIDA International Registry for patients with undifferentiated systemic autoinflammatory diseases. Front Med. 2022;9:908501.","journal-title":"Front Med"},{"issue":"10","key":"3936_CR24","doi-asserted-by":"publisher","first-page":"1256243","DOI":"10.3389\/fmed.2023.1256243","volume":"12","author":"A Vitale","year":"2023","unstructured":"Vitale A, Caggiano V, Sfikakis PP, et al. Efficacy of canakinumab in patients with Still\u2019s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still\u2019s Disease. Front Med (Lausanne). 2023;12(10):1256243.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"3936_CR25","first-page":"729","volume":"83","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Mitrovic S, De Matteis A, Bindoli S, Ant\u00f3n J, Belot A, et al. EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis. 2024;83(5):729\u201347.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3936_CR26","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s10067-023-06578-9","volume":"42","author":"RM Yip","year":"2023","unstructured":"Yip RM, Cheung TT, So H, Chan JP, Ho CT, Tsang HH, et al. The Hong Kong Society of Rheumatology consensus recommendations for the management of gout. Clin Rheumatol. 2023;42(8):2013\u201327.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"3936_CR27","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1111\/epi.17397","volume":"63","author":"R Wickstrom","year":"2022","unstructured":"Wickstrom R, Taraschenko O, Dilena R, Payne ET, Specchio N, Nabbout R, et al. International consensus recommendations for management of new onset refractory status epilepticus including febrile infection-related epilepsy syndrome: statements and supporting evidence. Epilepsia. 2022;63(11):2840\u201364.","journal-title":"Epilepsia"},{"issue":"6","key":"3936_CR28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","volume":"51","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody. Clin Pharmacokinet. 2012;51(6):e1\u201318.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3936_CR29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/JLB.5MR0120-218RRR","volume":"108","author":"AL Chetaille N\u00e9zondet","year":"2020","unstructured":"Chetaille N\u00e9zondet AL, Poubelle PE, Pelletier M. The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases. J Leukoc Biol. 2020;108(2):647\u201357.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"3936_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/ajmg.c.31990","volume":"190","author":"M Sambharia","year":"2022","unstructured":"Sambharia M, Rastogi P, Thomas CP. Monogenic focal segmental glomerulosclerosis: a conceptual framework for identification and management of a heterogeneous disease. Am J Med Genet C Semin Med Genet. 2022;190(3):377\u201398.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"4","key":"3936_CR31","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s12026-023-09375-3","volume":"71","author":"MT Hegazy","year":"2023","unstructured":"Hegazy MT, Fayed A, Nuzzolese R, Sota J, Ragab G. Autoinflammatory diseases and the kidney. Immunol Res. 2023;71(4):578\u201387.","journal-title":"Immunol Res"},{"issue":"2","key":"3936_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000536423","volume":"10","author":"J Li","year":"2024","unstructured":"Li J, Hou F, Lv N, Zhao R, Zhang L, Yue C, et al. From rare disorders of kidney tubules to acute renal injury: progress and prospective. Kidney Dis. 2024;10(2):153\u201366.","journal-title":"Kidney Dis"},{"issue":"5","key":"3936_CR33","first-page":"283","volume":"20","author":"S Ozen","year":"2024","unstructured":"Ozen S, Aksentijevich I. The past 25 years in pediatric rheumatology: insights from monogenic diseases. Nat Rev Rheumatol. 2024;20(5):283\u2013329.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"3936_CR34","first-page":"123","volume":"26","author":"AT Nguyen","year":"2024","unstructured":"Nguyen AT, Kon\u00e9-Paut I, Dusser P. Diagnosis and management of non-infectious uveitis in pediatric patients. Pediatr Drugs. 2024;26(2):123\u201335.","journal-title":"Pediatr Drugs"},{"issue":"6","key":"3936_CR35","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.semarthrit.2020.08.010","volume":"50","author":"A G\u00f3mez-G\u00f3mez","year":"2020","unstructured":"G\u00f3mez-G\u00f3mez A, Loza E, Rosario MP, Espinosa G, de Morales JMG, Herrera JM, et al. Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis, and macular edema: a systematic literature review. Semin Arthritis Rheum. 2020;50(6):1299\u2013306.","journal-title":"Semin Arthritis Rheum"},{"key":"3936_CR36","unstructured":"Akpinar \u00c7K. Autoimmune diseases of the central nervous system. Autoimmune Dis Diagn Approach. 2021;297."},{"issue":"5","key":"3936_CR37","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-3826","volume":"9","author":"Y Cui","year":"2021","unstructured":"Cui Y, Yang Y, Lei W, Lang X, Chen J. The clinicopathological features of drug-induced acute kidney injury\u2014a single-center retrospective analysis. Ann Transl Med. 2021;9(5):9742754.","journal-title":"Ann Transl Med"},{"issue":"1","key":"3936_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9742754","volume":"2020","author":"C Yu","year":"2020","unstructured":"Yu C, Guo D, Yao C, Yang H, Liu S, Zhu Y, et al. Clinical characteristics of hospitalized patients with drug\u2010induced acute kidney injury and associated risk factors: a case\u2010control study. BioMed Res Int. 2020;2020(1):9742754.","journal-title":"BioMed Res Int"},{"issue":"11","key":"3936_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22116109","volume":"22","author":"E Kwiatkowska","year":"2021","unstructured":"Kwiatkowska E, Doma\u0144ski L, Dziedziejko V, Kajdy A, Stefa\u0144ska K, Kwiatkowski S. The mechanism of drug nephrotoxicity and the methods for preventing kidney damage. Int J Mol Sci. 2021;22(11):6109.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3936_CR40","first-page":"123","volume":"13","author":"L Dobrek","year":"2023","unstructured":"Dobrek L. A synopsis of current theories on drug-induced nephrotoxicity. Life. 2023;13(4):123\u201334.","journal-title":"Life"},{"issue":"2","key":"3936_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000525561","volume":"147","author":"B Sanchez-Alamo","year":"2023","unstructured":"Sanchez-Alamo B, Cases-Corona C, Fernandez-Juarez G. Facing the challenge of drug-induced acute interstitial nephritis. Nephron. 2023;147(2):78\u201390.","journal-title":"Nephron"},{"issue":"3","key":"3936_CR42","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ckj\/sfab210","volume":"15","author":"A Bosi","year":"2022","unstructured":"Bosi A, Xu Y, Gasparini A, Wettermark B, Barany P, Bellocco R, et al. Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care. Clin Kidney J. 2022;15(3):442\u201351.","journal-title":"Clin Kidney J"},{"issue":"5","key":"3936_CR43","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1007\/s12325-023-02481-6","volume":"40","author":"JM LaForge","year":"2023","unstructured":"LaForge JM, Urso K, Day JM, Bourgeois CW, Ross MM, Ahmadzadeh S, et al. Non-steroidal anti-inflammatory drugs: clinical implications, renal impairment risks, and AKI. Adv Ther. 2023;40(5):2082\u201396.","journal-title":"Adv Ther"},{"issue":"3","key":"3936_CR44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/ijp.IJP_704_20","volume":"53","author":"VS Swathi","year":"2021","unstructured":"Swathi VS, Saroha S, Prakash J, Bhushan S. Retrospective pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease. Indian J Pharmacol. 2021;53(3):192\u20137.","journal-title":"Indian J Pharmacol"},{"key":"3936_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2021.09.008","volume":"96","author":"RJ Unwin","year":"2022","unstructured":"Unwin RJ. Toxic nephropathy: adverse renal effects caused by drugs. Eur J Intern Med. 2022;96:1\u201310.","journal-title":"Eur J Intern Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-03936-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-03936-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-03936-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:45:42Z","timestamp":1771926342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-03936-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3936"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-03936-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"346"}}